179 related articles for article (PubMed ID: 14769349)
1. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
Hartmann A; Hunot S; Hirsch EC
Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
[No Abstract] [Full Text] [Related]
2. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease.
Uhl GR
Ann Neurol; 1998 May; 43(5):555-60. PubMed ID: 9585349
[No Abstract] [Full Text] [Related]
3. The functional anatomy of noradrenergic neurons in Parkinson's disease.
Soldani P; Fornai F
Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
[No Abstract] [Full Text] [Related]
4. Endogenous regeneration in Parkinson's disease: do we need orthotopic dopaminergic neurogenesis?
Hermann A; Storch A
Stem Cells; 2008 Nov; 26(11):2749-52. PubMed ID: 18719222
[No Abstract] [Full Text] [Related]
5. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
6. Inflammation and neurodegeneration in Parkinson's disease.
McGeer PL; McGeer EG
Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
[TBL] [Abstract][Full Text] [Related]
7. Pathological dynamics of activated microglia following medial forebrain bundle transection.
Cho BP; Song DY; Sugama S; Shin DH; Shimizu Y; Kim SS; Kim YS; Joh TH
Glia; 2006 Jan; 53(1):92-102. PubMed ID: 16206155
[TBL] [Abstract][Full Text] [Related]
8. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
[TBL] [Abstract][Full Text] [Related]
9. Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.
Vivekanantham S; Shah S; Dewji R; Dewji A; Khatri C; Ologunde R
Int J Neurosci; 2015; 125(10):717-25. PubMed ID: 25364880
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
Liu B; Dluzen DE
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
[TBL] [Abstract][Full Text] [Related]
11. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
12. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
13. Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.
Maguire-Zeiss KA; Mhyre TR; Federoff HJ
Exp Neurol; 2008 Jan; 209(1):101-13. PubMed ID: 18035353
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Lee DY; Oh YJ; Jin BK
Glia; 2005 Aug; 51(2):98-110. PubMed ID: 15789435
[TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
16. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS.
Rodriguez-Pallares J; Rey P; Parga JA; Muñoz A; Guerra MJ; Labandeira-Garcia JL
Neurobiol Dis; 2008 Jul; 31(1):58-73. PubMed ID: 18499466
[TBL] [Abstract][Full Text] [Related]
17. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
18. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
[TBL] [Abstract][Full Text] [Related]
19. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
20. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease.
Matzuk MM; Saper CB
Ann Neurol; 1985 Nov; 18(5):552-5. PubMed ID: 4073850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
